SynthesisFrontiers in neurology
Quantitative ophthalmic posterior segment optical coherence tomography angiography and neurologic conditions: a review.
Synthesis in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the potential of quantitative ophthalmic posterior segment optical coherence tomography angiography (OCTA) imaging metrics to serve as biomarkers for systemic involvement in five neurologic diseases (multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, Alzheimer disease, and Parkinson disease) by reviewing the reported correlations between such OCTA metrics and clinically relevant features of systemic involvement in these diseases. Methods: This article is a literature review of the PubMed database for articles reporting OCTA metrics in any of the included neurologic diseases. Articles correlating quantitative retinal, optic nerve head, or choriocapillaris OCTA metrics to clinically relevant features of systemic involvement, specifically serum, cerebrospinal fluid (CSF), or other established biomarkers; genotype; systemic symptom and severity scores; stage; non-ocular organ involvement; brain or other non-ocular imaging findings; and systemic medication use were included. Results: OCTA parameters have been significantly correlated to established biomarkers, severity scores, non-ocular organ involvement and imaging findings, and systemic medication use in multiple sclerosis. OCTA parameters have been significantly correlated to established biomarkers, severity scores, and non-ocular organ involvement and imaging findings in neuromyelitis optica spectrum disorder. OCTA parameters have been significantly correlated to severity scores in myelin oligodendrocyte glycoprotein antibody-associated disease. OCTA parameters have been significantly correlated to established biomarkers, genotype, severity scores, disease stage, and non-ocular organ involvement and imaging findings in Alzheimer disease. OCTA parameters have been significantly correlated to severity scores, disease stage, and non-ocular organ involvement in Parkinson disease. Conclusion: Our findings suggest that ophthalmic posterior segment OCTA might improve our understanding of the pathophysiology of systemic neurologic conditions, including those that do not traditionally affect the eye, and might identify biomarkers useful in the diagnosis, prognosis, and management of these conditions, justifying further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.